Drug Approval | October 02, 2024
Zydus receives tentative approval from USFDA for Enzalutamide Tablets
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
The company will also share results in two additional posters for deuruxolitinib
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
ALS patients experience neuroinflammation and rapid neurodegeneration
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Subscribe To Our Newsletter & Stay Updated
